Genmab — September 2018
-
Det Jan omtalte fra Journal of clinical oncology: "Conclusion:
Baseline corticosteroid use of ≥ 10 mg of prednisone equivalent was associated with poorer outcome in patients with non–small-cell lung cancer who were treated with PD-(L)1 blockade. Prudent use of corticosteroids at the time of initiating PD-(L)1 blockade is recommended." -
-
Winkel var inde på at isatuximab-folkene måske havde knækket koden i solide. I hvert fald fastholder de kombi-forsøget med Cemiplimab (PD-1 blokker) i prostata cancer og nsclc https://www.clinicaltrials.gov/ct2/show/NCT03367819?term=isatuximab+nsclc&rank=1
-
-
Her er det nye studie, som Winkel omtaler, med isa i diverse solide https://www.clinicaltrials.gov/ct2/show/NCT03637764?term=isatuximab&draw=2&rank=11
-
@Bulder/Sukkeralf/Solsen - I går udtalte Jan at DR5 var 100 gange mere potent end en nøgen antibody. Er dara eller ofa en nøgen antibody? Vil det sige at der er mulighed for at DR5 kan udvikle sig til et meget kraftigere medicament
end f.eks. dara? -
DR5 er vel rettet mod solide. Så DR5 kan have stærkere virkning end nøgen antistof, men også en større risiko for bivirkninger. Rigitg forstået?
-
Tak Solsen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind